Physician profile
Michael D Marsh
NPI 1710243027
$5,113.18
in general payments reported to CMS, 2019-2025
30 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what 81% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $97.21 · 2021: $187 · 2022: $223 · 2023: $601 · 2024: $1,339 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,319 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,319.02 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,598.41 | 2020-2025 | Briviact, Fintepla, Nayzilam |
| Corium, LLC | $500.37 | 2022-2025 | Azstarys |
| Otter Pharmaceuticals, LLC | $405.06 | 2024-2025 | Sympazan |
| Livanova USA, INC. | $389.30 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $294.70 | 2022-2025 | Epidiolex |
| Acadia Pharmaceuticals INC | $242.78 | 2023-2025 | Daybue |
| Neurelis, INC. | $227.08 | 2023-2025 | Valtoco |
| Biogen, INC. | $142.01 | 2019 | |
| Upsher-Smith Laboratories LLC | $126.55 | 2023-2025 | |
| Glaxosmithkline, LLC. | $125.00 | 2025 | Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $121.32 | 2019-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $115.62 | 2023-2025 | Dyanavel Xr |
| Azurity Pharmaceuticals, INC. | $110.92 | 2024-2025 | Zonisade |
| Catalyst Pharmaceuticals, INC. | $94.40 | 2024-2025 | |
| Shire North American Group INC | $85.09 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zogenix INC. | $59.73 | 2020-2021 | |
| Pyros Pharmaceuticals, INC. | $59.16 | 2024 | Vigpoder |
| Abbvie INC. | $57.60 | 2021 | |
| Biocodex, INC. | $57.27 | 2023 | Diacomit |
| Aucta Pharmaceuticals, INC. | $52.56 | 2025 | Motpoly Xr |
| Eisai INC. | $42.27 | 2020-2023 | |
| Greenwich Biosciences, INC. | $39.55 | 2021 | |
| Springworks Therapeutics, INC. | $33.92 | 2025 | Gomekli |
| Aquestive Therapeutics, INC. | $25.34 | 2024 | |
| Itf Therapeutics LLC | $24.92 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.52 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.37 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.17 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $15.90 | 2024 | Subvenite |
| Medtronic USA, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.